US FDA Biologics Group Emerging From Pandemic Footing – But Not Vaccines
Executive Summary
The COVID-19 pandemic is definitely not over when it comes to the workload facing the US FDA’s vaccine review team, even as the other biologics review operations get back ‘toward normal.’
You may also be interested in...
US FDA’s Marks Was Frustrated About Slow Completion Of 2021 Comirnaty Review
CBER Director Peter Marks told Janet Woodcock in an email that he thought reviewers were treating the BLA for the first fully approved COVID-19 vaccine as a conventional review or learning exercise.
New Name, Old Problems: US FDA’s Cell And Gene Therapy Office Still Facing Growth Challenges
The group will be called the Office of Therapeutic Products, but needs more people to handle its increasing workload.
CBER’s Goal To Reach Normal Ops In 2023 Includes Clearing IND, Meeting Backlogs In 2022
CBER director Peter Marks also wants to work on rare disease gene therapy issues and increase hiring before the end of the year.